SEC Form 4 · accession 0000899243-18-029668
Urovant Sciences Ltd. · UROV
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Sef Kurstjens
Director
Period of report
Nov 21, 2018
Accepted (ET)
Nov 26, 2018 · 8:37 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001740547
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $8.01 | Nov 21, 2018 | A | 36,650 | A | — | Nov 21, 2028 | Common Shares | 36,650 | 36,650 | D |
Explanation of responses
- F1The shares underlying the option shall vest and become exercisable in three equal annual installments beginning on November 9, 2019, subject to the Reporting Person providing continuous service to the Issuer through each such vesting date.
Remarks
Exhibit List - Exhibit 24.1 - Power of Attorney